US2016136281A1PendingUtilityA1

Delivery of ibuprofen and other compounds

56
Assignee: STRATEGIC SCIENCE & TECH LLCPriority: Jun 24, 2009Filed: Jan 21, 2016Published: May 19, 2016
Est. expiryJun 24, 2029(~2.9 yrs left)· nominal 20-yr term from priority
Inventors:Eric T. Fossel
A61P 29/00A61K 47/02A61K 9/06A61K 9/7023A61K 47/12A61K 47/10A61K 9/0014A61K 31/522A61K 47/36A61K 9/127A61K 9/107A61K 47/26A61K 31/192
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 112 . (canceled) 
     
     
         113 . A composition for topical delivery to the skin of a subject, the composition comprising:
 a stabilization polymer comprising xanthan gum;   propylene glycol;   a polysorbate surfactant; and   an ionic strength of at least about 0.25 M.   
     
     
         114 . The composition of  claim 113 , wherein the composition further comprises a nitric oxide donor. 
     
     
         115 . The composition of  claim 114 , wherein the nitric oxide donor comprises L-arginine. 
     
     
         116 . The composition of  claim 114 , wherein the nitric oxide donor comprises an L-arginine salt. 
     
     
         117 . The composition of  claim 114 , wherein the nitric oxide donor is present at a concentration of at least about 0.5% by weight of the composition. 
     
     
         118 . The composition of  claim 113 , wherein the composition comprises an ionic strength of at least about 1 M. 
     
     
         119 . The composition of  claim 113 , wherein the composition comprises an ionic salt. 
     
     
         120 . The composition of  claim 119 , wherein the ionic salt comprises sodium chloride. 
     
     
         121 . The composition of  claim 119 , wherein the ionic salt comprises one or more of choline chloride, magnesium chloride, and calcium chloride. 
     
     
         122 . The composition of  claim 119 , wherein the ionic salt is present in a concentration of at least about 5% by weight of the composition. 
     
     
         123 . The composition of  claim 113 , wherein the composition comprises one or more changed polymers. 
     
     
         124 . The composition of  claim 123 , wherein the one or more charged polymers comprises one or more of polylysine, polyglutamine, and polyaspartate. 
     
     
         125 . The composition of  claim 113 , wherein the composition further comprises a penetrating agent. 
     
     
         126 . The composition of  claim 113 , wherein the composition further comprises citric acid. 
     
     
         127 . The composition of  claim 113 , wherein the stabilization polymer is present in a concentration of at least about 0.5% by weight of the composition. 
     
     
         128 . The composition of  claim 113 , wherein the propylene glycol is present in a concentration of at least about 3% by weight of the composition. 
     
     
         129 . The composition of  claim 113 , wherein the polysorbate surfactant is present in a concentration of at least about 1% by weight of the composition. 
     
     
         130 . The composition of  claim 113 , wherein the polysorbate surfactant comprises Polysorbate 20. 
     
     
         131 . The composition of  claim 113 , wherein the composition is in a form selected from the group consisting of a cream, a gel, and a lotion. 
     
     
         132 . The composition of  claim 113 , wherein the composition further comprises one or more of glyceryl stearate, cetyl alcohol, squalene, isopropyl myristate, and oleic acid. 
     
     
         133 . The composition of  claim 113 , wherein the composition further comprises one or more pharmaceutical agents. 
     
     
         134 . The composition of  claim 133 , wherein the composition is able to deliver the one or more pharmaceutical agents systemically within the body of the subject. 
     
     
         135 . The composition of  claim 133 , wherein the composition is able to deliver the one or more pharmaceutical agents to a specific location within the body of the subject. 
     
     
         136 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises a small molecule, a peptide, a protein, a hormone, a vitamin, or a nucleic acid. 
     
     
         137 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an NSAID. 
     
     
         138 . The composition of  claim 137 , wherein the NSAID comprises one or more of acetylsalicylic acid, naproxen, celecoxib, or refecoxib. 
     
     
         139 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises a narcotic. 
     
     
         140 . The composition of  claim 139 , wherein the narcotic comprises one or more of morphine, codine, propoxyphene, oxycodone, or hydrocodone. 
     
     
         141 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an agent for treating sexual dysfunction. 
     
     
         142 . The composition of  claim 141 , wherein the agent for treating sexual dysfunction comprises one or more of yohimbie, alprostadil, sildenafil, cialis, uprima, or vardenaifl. 
     
     
         143 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an agent for treating migraine. 
     
     
         144 . The composition of  claim 143 , wherein the agent for treating migraine comprises one or more of dihydroergotamine, ergotamine, sumatripan, rizatriptan, or zolmitriptan. 
     
     
         145 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an agent for treating hair. 
     
     
         146 . The composition of  claim 145 , wherein the agent for treating hair comprises one or more of finasteride, eflornithine, or minoxidil. 
     
     
         147 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises a muscle improving agent. 
     
     
         148 . The composition of  claim 147 , wherein the muscle improving agent comprises creatine and/or a creatine precursor. 
     
     
         149 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an ATP precursor. 
     
     
         150 . The composition of  claim 149 , wherein the ATP precursor comprises one or more of inosine, adenosine, inosine, adenine, hypoxanthine, ribose, or phosphate. 
     
     
         151 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an anabolic steroid. 
     
     
         152 . The composition of  claim 151 , wherein the anabolic steroid comprises one or more of androstene, DHEA, androstenediol, androstenedione, ephedra, ephedrine, or pseudoephedrine 
     
     
         153 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an agent for treating cancer. 
     
     
         154 . The composition of  claim 153 , wherein the agent for treating cancer and/or viral infection comprises one or more of tamoxifen, cis-platin, carboplatin, cyclophosphamide, vinca alkaloids, epipodophyllotoxins, or taxol. 
     
     
         155 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises an agent for viral infection. 
     
     
         156 . The composition of  claim 155 , wherein the agent for treating cancer and/or viral infection comprises acyclovir. 
     
     
         157 . The composition of  claim 133 , wherein the one or more pharmaceutical agents comprises naicin, lidocaine, or benzocaine. 
     
     
         158 . The composition of  claim 113 , wherein the composition further comprises theophylline. 
     
     
         159 . The composition of  claim 113 , wherein the composition further comprises one or more of vitamin A, vitamin D, and vitamin E. 
     
     
         160 . The composition of  claim 113 , wherein the composition is tailored to have a duration of effective treatment of at least about 3 hours. 
     
     
         161 . The composition of  claim 113 , wherein the composition contains water at at least about 20 wt %. 
     
     
         162 . A method, comprising applying the composition of  claim 113  to a subject. 
     
     
         163 . The method of  claim 162 , wherein the subject is human. 
     
     
         164 . The method of  claim 162 , comprising applying the composition to the head of the subject. 
     
     
         165 . The method of  claim 162 , comprising applying the composition to the genitals of the subject. 
     
     
         166 . The method of  claim 162 , comprising applying the composition to a muscle of the subject. 
     
     
         167 . The method of  claim 162 , comprising applying the composition to a joint of the subject.

Join the waitlist — get patent alerts

Track US2016136281A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.